{"id":67403,"date":"2021-04-16T03:00:42","date_gmt":"2021-04-16T01:00:42","guid":{"rendered":"https:\/\/www.cde.ual.es\/?p=67403"},"modified":"2021-09-13T11:00:34","modified_gmt":"2021-09-13T09:00:34","slug":"vaccine-janssen-assessment-of-very-rare-cases-of-unusual-blood-clots-with-low-platelets-continues","status":"publish","type":"post","link":"https:\/\/www.cde.ual.es\/en\/vaccine-janssen-assessment-of-very-rare-cases-of-unusual-blood-clots-with-low-platelets-continues\/","title":{"rendered":"Vaccine Janssen: assessment of very rare cases of unusual blood clots with low platelets continues"},"content":{"rendered":"<p>EMA\u2019s safety committee (PRAC) is reviewing very rare cases of unusual blood clots that occurred in the United States following the use of Janssen\u2019s COVID-19 vaccine. The type of blood clot reported, cerebral venous sinus thrombosis (CVST), occurred in most cases in combination with low levels of blood platelets (thrombocytopenia).<\/p>\n<p><a href=\"https:\/\/www.cde.ual.es\/wp-content\/uploads\/2021\/04\/steven-cornfield-jWPNYZdGz78-unsplash-scaled.jpg\"><img decoding=\"async\" class=\" wp-image-67414 aligncenter\" src=\"https:\/\/www.cde.ual.es\/wp-content\/uploads\/2021\/04\/steven-cornfield-jWPNYZdGz78-unsplash-300x200.jpg\" alt=\"\" width=\"402\" height=\"268\" srcset=\"https:\/\/www.cde.ual.es\/wp-content\/uploads\/2021\/04\/steven-cornfield-jWPNYZdGz78-unsplash-300x200.jpg 300w, https:\/\/www.cde.ual.es\/wp-content\/uploads\/2021\/04\/steven-cornfield-jWPNYZdGz78-unsplash-1024x683.jpg 1024w, https:\/\/www.cde.ual.es\/wp-content\/uploads\/2021\/04\/steven-cornfield-jWPNYZdGz78-unsplash-768x512.jpg 768w, https:\/\/www.cde.ual.es\/wp-content\/uploads\/2021\/04\/steven-cornfield-jWPNYZdGz78-unsplash-1536x1024.jpg 1536w, https:\/\/www.cde.ual.es\/wp-content\/uploads\/2021\/04\/steven-cornfield-jWPNYZdGz78-unsplash-2048x1365.jpg 2048w\" sizes=\"(max-width: 402px) 100vw, 402px\" \/><\/a><\/p>\n<p>The US FDA and CDC recommended that the use of the vaccine should be paused while they review six reported cases in the United States. More than 6.8 million doses of the vaccine have been administered.<\/p>\n<p>Janssen has announced their\u00a0decision to proactively delay the rollout of the vaccine in the EU\u00a0while investigations continue. The vaccine was authorised in the EU on 11 March 2021 but widespread use of the vaccine within the EU has not yet started. The company is in contact with national authorities, recommending to store the doses already received until the\u00a0PRAC\u00a0issues an expedited recommendation.<\/p>\n<p>EMA is investigating all the cases reported and will decide whether regulatory action is necessary. The Agency is working closely with the US FDA and other international regulators.<\/p>\n<p>EMA is expediting this evaluation and currently expects to issue a recommendation next week. While its review is ongoing, EMA remains of the view that the benefits of the vaccine in preventing COVID-19 outweigh the risks of side effects. The Agency\u2019s scientific opinions provide EU Member States with the information they need to take decisions on the use of vaccines in their national vaccination campaigns.<\/p>\n<h3>More about the vaccine<\/h3>\n<p>COVID-19 Vaccine Janssen is a vaccine for preventing coronavirus disease 2019 (COVID-19) in people aged 18 years and older. It is made up of another virus (of the adenovirus family) that has been modified to contain the gene for making a protein found on SARS-CoV-2.<\/p>\n<p>The most common side effects with COVID-19 Vaccine Janssen are usually mild or moderate and get better within 1 or 2 days after vaccination.<\/p>\n<h3>More about the procedure<\/h3>\n<p>The review is being carried out in the context of a\u00a0safety signal, under an accelerated timetable. A\u00a0safety signal\u00a0is information on a new or incompletely documented\u00a0adverse event\u00a0that is potentially caused by a medicine such as a vaccine and that warrants further investigation.<strong>\u00a0<\/strong>The presence of a\u00a0safety signal\u00a0does not necessarily mean that a medicine has caused the reported\u00a0adverse event. The assessment of\u00a0safety signals\u00a0seeks to establish whether a causal relationship between the medicine and the\u00a0adverse event\u00a0is at least a reasonable possibility.<\/p>\n<p>The review is being carried out by EMA\u2019s\u00a0Pharmacovigilance Risk Assessment Committee\u00a0(PRAC), the committee responsible for the evaluation of safety issues for human medicines. Once the review is completed,\u00a0PRAC\u00a0will make any recommendations necessary to minimise risks and protect people\u2019s health.<\/p>\n<h3>More information<\/h3>\n<p><a href=\"https:\/\/www.ema.europa.eu\/en\/news\/covid-19-vaccine-janssen-assessment-very-rare-cases-unusual-blood-clots-low-platelets-continues\" target=\"_blank\" rel=\"noopener\">European Medicines Agency &#8211; Press Release<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>EMA\u2019s safety committee (PRAC) is reviewing very rare cases of unusual blood clots that occurred in the United States following the use of Janssen\u2019s COVID-19 vaccine. The type of blood clot reported, cerebral venous sinus thrombosis (CVST), occurred in most cases in combination with low levels of blood platelets (thrombocytopenia). The US FDA and CDC [&hellip;]<\/p>\n","protected":false},"author":101012,"featured_media":67414,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_relevanssi_hide_post":"","_relevanssi_hide_content":"","_relevanssi_pin_for_all":"","_relevanssi_pin_keywords":"","_relevanssi_unpin_keywords":"","_relevanssi_related_keywords":"","_relevanssi_related_include_ids":"","_relevanssi_related_exclude_ids":"","_relevanssi_related_no_append":"","_relevanssi_related_not_related":"","_relevanssi_related_posts":"","_relevanssi_noindex_reason":"","_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"_genesis_hide_title":false,"_genesis_hide_breadcrumbs":false,"_genesis_hide_singular_image":false,"_genesis_hide_footer_widgets":false,"_genesis_custom_body_class":"","_genesis_custom_post_class":"","_genesis_layout":"","footnotes":""},"categories":[346,4094,4092],"tags":[2448,2670,700],"class_list":{"0":"post-67403","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-eu-news","8":"category-farmac","9":"category-health","10":"tag-covid","11":"tag-european-medicines-agency","12":"tag-vaccine-en","13":"entry"},"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Vaccine Janssen: assessment of very rare cases of unusual blood clots with low platelets continues | CDE Almer\u00eda - Centro de Documentaci\u00f3n Europea - Universidad de Almer\u00eda<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.cde.ual.es\/en\/vaccine-janssen-assessment-of-very-rare-cases-of-unusual-blood-clots-with-low-platelets-continues\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Vaccine Janssen: assessment of very rare cases of unusual blood clots with low platelets continues | CDE Almer\u00eda - Centro de Documentaci\u00f3n Europea - Universidad de Almer\u00eda\" \/>\n<meta property=\"og:description\" content=\"EMA\u2019s safety committee (PRAC) is reviewing very rare cases of unusual blood clots that occurred in the United States following the use of Janssen\u2019s COVID-19 vaccine. The type of blood clot reported, cerebral venous sinus thrombosis (CVST), occurred in most cases in combination with low levels of blood platelets (thrombocytopenia). The US FDA and CDC [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.cde.ual.es\/en\/vaccine-janssen-assessment-of-very-rare-cases-of-unusual-blood-clots-with-low-platelets-continues\/\" \/>\n<meta property=\"og:site_name\" content=\"CDE Almer\u00eda - Centro de Documentaci\u00f3n Europea - Universidad de Almer\u00eda\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/cdeuniversidadalmeria\/\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-16T01:00:42+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-09-13T09:00:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.cde.ual.es\/wp-content\/uploads\/2021\/04\/steven-cornfield-jWPNYZdGz78-unsplash-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1707\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"BECACDE1\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@cdeualmeria\" \/>\n<meta name=\"twitter:site\" content=\"@cdeualmeria\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"BECACDE1\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.cde.ual.es\\\/en\\\/vaccine-janssen-assessment-of-very-rare-cases-of-unusual-blood-clots-with-low-platelets-continues\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.cde.ual.es\\\/en\\\/vaccine-janssen-assessment-of-very-rare-cases-of-unusual-blood-clots-with-low-platelets-continues\\\/\"},\"author\":{\"name\":\"BECACDE1\",\"@id\":\"https:\\\/\\\/www.cde.ual.es\\\/#\\\/schema\\\/person\\\/bf2f837cf3353e2161fe1087adbd728f\"},\"headline\":\"Vaccine Janssen: assessment of very rare cases of unusual blood clots with low platelets continues\",\"datePublished\":\"2021-04-16T01:00:42+00:00\",\"dateModified\":\"2021-09-13T09:00:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.cde.ual.es\\\/en\\\/vaccine-janssen-assessment-of-very-rare-cases-of-unusual-blood-clots-with-low-platelets-continues\\\/\"},\"wordCount\":475,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/www.cde.ual.es\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.cde.ual.es\\\/en\\\/vaccine-janssen-assessment-of-very-rare-cases-of-unusual-blood-clots-with-low-platelets-continues\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.cde.ual.es\\\/wp-content\\\/uploads\\\/2021\\\/04\\\/steven-cornfield-jWPNYZdGz78-unsplash-scaled.jpg\",\"keywords\":[\"Covid\",\"European Medicines Agency\",\"vaccine\"],\"articleSection\":[\"EU News\",\"Farmaceutical\",\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.cde.ual.es\\\/en\\\/vaccine-janssen-assessment-of-very-rare-cases-of-unusual-blood-clots-with-low-platelets-continues\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.cde.ual.es\\\/en\\\/vaccine-janssen-assessment-of-very-rare-cases-of-unusual-blood-clots-with-low-platelets-continues\\\/\",\"url\":\"https:\\\/\\\/www.cde.ual.es\\\/en\\\/vaccine-janssen-assessment-of-very-rare-cases-of-unusual-blood-clots-with-low-platelets-continues\\\/\",\"name\":\"Vaccine Janssen: assessment of very rare cases of unusual blood clots with low platelets continues | CDE Almer\u00eda - Centro de Documentaci\u00f3n Europea - Universidad de Almer\u00eda\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.cde.ual.es\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.cde.ual.es\\\/en\\\/vaccine-janssen-assessment-of-very-rare-cases-of-unusual-blood-clots-with-low-platelets-continues\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.cde.ual.es\\\/en\\\/vaccine-janssen-assessment-of-very-rare-cases-of-unusual-blood-clots-with-low-platelets-continues\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.cde.ual.es\\\/wp-content\\\/uploads\\\/2021\\\/04\\\/steven-cornfield-jWPNYZdGz78-unsplash-scaled.jpg\",\"datePublished\":\"2021-04-16T01:00:42+00:00\",\"dateModified\":\"2021-09-13T09:00:34+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.cde.ual.es\\\/en\\\/vaccine-janssen-assessment-of-very-rare-cases-of-unusual-blood-clots-with-low-platelets-continues\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.cde.ual.es\\\/en\\\/vaccine-janssen-assessment-of-very-rare-cases-of-unusual-blood-clots-with-low-platelets-continues\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.cde.ual.es\\\/en\\\/vaccine-janssen-assessment-of-very-rare-cases-of-unusual-blood-clots-with-low-platelets-continues\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.cde.ual.es\\\/wp-content\\\/uploads\\\/2021\\\/04\\\/steven-cornfield-jWPNYZdGz78-unsplash-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/www.cde.ual.es\\\/wp-content\\\/uploads\\\/2021\\\/04\\\/steven-cornfield-jWPNYZdGz78-unsplash-scaled.jpg\",\"width\":2560,\"height\":1707},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.cde.ual.es\\\/en\\\/vaccine-janssen-assessment-of-very-rare-cases-of-unusual-blood-clots-with-low-platelets-continues\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Inicio\",\"item\":\"https:\\\/\\\/www.cde.ual.es\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"EU News\",\"item\":\"https:\\\/\\\/www.cde.ual.es\\\/en\\\/category\\\/eu-news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Health\",\"item\":\"https:\\\/\\\/www.cde.ual.es\\\/en\\\/category\\\/eu-news\\\/health\\\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Farmaceutical\",\"item\":\"https:\\\/\\\/www.cde.ual.es\\\/en\\\/category\\\/eu-news\\\/health\\\/farmac\\\/\"},{\"@type\":\"ListItem\",\"position\":5,\"name\":\"Vaccine Janssen: assessment of very rare cases of unusual blood clots with low platelets continues\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.cde.ual.es\\\/#website\",\"url\":\"https:\\\/\\\/www.cde.ual.es\\\/\",\"name\":\"CDE Almer\u00eda - Centro de Documentaci\u00f3n Europea - Universidad de Almer\u00eda\",\"description\":\"Centro de Documentaci\u00f3n Europea de la Universidad de Almer\u00eda\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.cde.ual.es\\\/#organization\"},\"alternateName\":\"CDE Almer\u00eda\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.cde.ual.es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.cde.ual.es\\\/#organization\",\"name\":\"Centro de Documentaci\u00f3n Europea de Almer\u00eda\",\"url\":\"https:\\\/\\\/www.cde.ual.es\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.cde.ual.es\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.cde.ual.es\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/cde-logo-3.png\",\"contentUrl\":\"https:\\\/\\\/www.cde.ual.es\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/cde-logo-3.png\",\"width\":1400,\"height\":300,\"caption\":\"Centro de Documentaci\u00f3n Europea de Almer\u00eda\"},\"image\":{\"@id\":\"https:\\\/\\\/www.cde.ual.es\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/cdeuniversidadalmeria\\\/\",\"https:\\\/\\\/x.com\\\/cdeualmeria\",\"https:\\\/\\\/www.tiktok.com\\\/@cdealmeria\",\"https:\\\/\\\/www.instagram.com\\\/cdealmeria\\\/\",\"https:\\\/\\\/www.linkedin.com\\\/in\\\/cde-almera-812b26a9\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.cde.ual.es\\\/#\\\/schema\\\/person\\\/bf2f837cf3353e2161fe1087adbd728f\",\"name\":\"BECACDE1\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/16a4c1e422b5dec818ee13eab3353b19db9cfd278cc10f9b0e1188a37671d9d4?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/16a4c1e422b5dec818ee13eab3353b19db9cfd278cc10f9b0e1188a37671d9d4?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/16a4c1e422b5dec818ee13eab3353b19db9cfd278cc10f9b0e1188a37671d9d4?s=96&d=mm&r=g\",\"caption\":\"BECACDE1\"},\"sameAs\":[\"http:\\\/\\\/www.cdealmeria.com\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Vaccine Janssen: assessment of very rare cases of unusual blood clots with low platelets continues | CDE Almer\u00eda - Centro de Documentaci\u00f3n Europea - Universidad de Almer\u00eda","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.cde.ual.es\/en\/vaccine-janssen-assessment-of-very-rare-cases-of-unusual-blood-clots-with-low-platelets-continues\/","og_locale":"en_US","og_type":"article","og_title":"Vaccine Janssen: assessment of very rare cases of unusual blood clots with low platelets continues | CDE Almer\u00eda - Centro de Documentaci\u00f3n Europea - Universidad de Almer\u00eda","og_description":"EMA\u2019s safety committee (PRAC) is reviewing very rare cases of unusual blood clots that occurred in the United States following the use of Janssen\u2019s COVID-19 vaccine. The type of blood clot reported, cerebral venous sinus thrombosis (CVST), occurred in most cases in combination with low levels of blood platelets (thrombocytopenia). The US FDA and CDC [&hellip;]","og_url":"https:\/\/www.cde.ual.es\/en\/vaccine-janssen-assessment-of-very-rare-cases-of-unusual-blood-clots-with-low-platelets-continues\/","og_site_name":"CDE Almer\u00eda - Centro de Documentaci\u00f3n Europea - Universidad de Almer\u00eda","article_publisher":"https:\/\/www.facebook.com\/cdeuniversidadalmeria\/","article_published_time":"2021-04-16T01:00:42+00:00","article_modified_time":"2021-09-13T09:00:34+00:00","og_image":[{"width":2560,"height":1707,"url":"https:\/\/www.cde.ual.es\/wp-content\/uploads\/2021\/04\/steven-cornfield-jWPNYZdGz78-unsplash-scaled.jpg","type":"image\/jpeg"}],"author":"BECACDE1","twitter_card":"summary_large_image","twitter_creator":"@cdeualmeria","twitter_site":"@cdeualmeria","twitter_misc":{"Written by":"BECACDE1","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.cde.ual.es\/en\/vaccine-janssen-assessment-of-very-rare-cases-of-unusual-blood-clots-with-low-platelets-continues\/#article","isPartOf":{"@id":"https:\/\/www.cde.ual.es\/en\/vaccine-janssen-assessment-of-very-rare-cases-of-unusual-blood-clots-with-low-platelets-continues\/"},"author":{"name":"BECACDE1","@id":"https:\/\/www.cde.ual.es\/#\/schema\/person\/bf2f837cf3353e2161fe1087adbd728f"},"headline":"Vaccine Janssen: assessment of very rare cases of unusual blood clots with low platelets continues","datePublished":"2021-04-16T01:00:42+00:00","dateModified":"2021-09-13T09:00:34+00:00","mainEntityOfPage":{"@id":"https:\/\/www.cde.ual.es\/en\/vaccine-janssen-assessment-of-very-rare-cases-of-unusual-blood-clots-with-low-platelets-continues\/"},"wordCount":475,"commentCount":0,"publisher":{"@id":"https:\/\/www.cde.ual.es\/#organization"},"image":{"@id":"https:\/\/www.cde.ual.es\/en\/vaccine-janssen-assessment-of-very-rare-cases-of-unusual-blood-clots-with-low-platelets-continues\/#primaryimage"},"thumbnailUrl":"https:\/\/www.cde.ual.es\/wp-content\/uploads\/2021\/04\/steven-cornfield-jWPNYZdGz78-unsplash-scaled.jpg","keywords":["Covid","European Medicines Agency","vaccine"],"articleSection":["EU News","Farmaceutical","Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.cde.ual.es\/en\/vaccine-janssen-assessment-of-very-rare-cases-of-unusual-blood-clots-with-low-platelets-continues\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.cde.ual.es\/en\/vaccine-janssen-assessment-of-very-rare-cases-of-unusual-blood-clots-with-low-platelets-continues\/","url":"https:\/\/www.cde.ual.es\/en\/vaccine-janssen-assessment-of-very-rare-cases-of-unusual-blood-clots-with-low-platelets-continues\/","name":"Vaccine Janssen: assessment of very rare cases of unusual blood clots with low platelets continues | CDE Almer\u00eda - Centro de Documentaci\u00f3n Europea - Universidad de Almer\u00eda","isPartOf":{"@id":"https:\/\/www.cde.ual.es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.cde.ual.es\/en\/vaccine-janssen-assessment-of-very-rare-cases-of-unusual-blood-clots-with-low-platelets-continues\/#primaryimage"},"image":{"@id":"https:\/\/www.cde.ual.es\/en\/vaccine-janssen-assessment-of-very-rare-cases-of-unusual-blood-clots-with-low-platelets-continues\/#primaryimage"},"thumbnailUrl":"https:\/\/www.cde.ual.es\/wp-content\/uploads\/2021\/04\/steven-cornfield-jWPNYZdGz78-unsplash-scaled.jpg","datePublished":"2021-04-16T01:00:42+00:00","dateModified":"2021-09-13T09:00:34+00:00","breadcrumb":{"@id":"https:\/\/www.cde.ual.es\/en\/vaccine-janssen-assessment-of-very-rare-cases-of-unusual-blood-clots-with-low-platelets-continues\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.cde.ual.es\/en\/vaccine-janssen-assessment-of-very-rare-cases-of-unusual-blood-clots-with-low-platelets-continues\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.cde.ual.es\/en\/vaccine-janssen-assessment-of-very-rare-cases-of-unusual-blood-clots-with-low-platelets-continues\/#primaryimage","url":"https:\/\/www.cde.ual.es\/wp-content\/uploads\/2021\/04\/steven-cornfield-jWPNYZdGz78-unsplash-scaled.jpg","contentUrl":"https:\/\/www.cde.ual.es\/wp-content\/uploads\/2021\/04\/steven-cornfield-jWPNYZdGz78-unsplash-scaled.jpg","width":2560,"height":1707},{"@type":"BreadcrumbList","@id":"https:\/\/www.cde.ual.es\/en\/vaccine-janssen-assessment-of-very-rare-cases-of-unusual-blood-clots-with-low-platelets-continues\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Inicio","item":"https:\/\/www.cde.ual.es\/en\/"},{"@type":"ListItem","position":2,"name":"EU News","item":"https:\/\/www.cde.ual.es\/en\/category\/eu-news\/"},{"@type":"ListItem","position":3,"name":"Health","item":"https:\/\/www.cde.ual.es\/en\/category\/eu-news\/health\/"},{"@type":"ListItem","position":4,"name":"Farmaceutical","item":"https:\/\/www.cde.ual.es\/en\/category\/eu-news\/health\/farmac\/"},{"@type":"ListItem","position":5,"name":"Vaccine Janssen: assessment of very rare cases of unusual blood clots with low platelets continues"}]},{"@type":"WebSite","@id":"https:\/\/www.cde.ual.es\/#website","url":"https:\/\/www.cde.ual.es\/","name":"CDE Almer\u00eda - Centro de Documentaci\u00f3n Europea - Universidad de Almer\u00eda","description":"Centro de Documentaci\u00f3n Europea de la Universidad de Almer\u00eda","publisher":{"@id":"https:\/\/www.cde.ual.es\/#organization"},"alternateName":"CDE Almer\u00eda","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.cde.ual.es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.cde.ual.es\/#organization","name":"Centro de Documentaci\u00f3n Europea de Almer\u00eda","url":"https:\/\/www.cde.ual.es\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.cde.ual.es\/#\/schema\/logo\/image\/","url":"https:\/\/www.cde.ual.es\/wp-content\/uploads\/2025\/07\/cde-logo-3.png","contentUrl":"https:\/\/www.cde.ual.es\/wp-content\/uploads\/2025\/07\/cde-logo-3.png","width":1400,"height":300,"caption":"Centro de Documentaci\u00f3n Europea de Almer\u00eda"},"image":{"@id":"https:\/\/www.cde.ual.es\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/cdeuniversidadalmeria\/","https:\/\/x.com\/cdeualmeria","https:\/\/www.tiktok.com\/@cdealmeria","https:\/\/www.instagram.com\/cdealmeria\/","https:\/\/www.linkedin.com\/in\/cde-almera-812b26a9\/"]},{"@type":"Person","@id":"https:\/\/www.cde.ual.es\/#\/schema\/person\/bf2f837cf3353e2161fe1087adbd728f","name":"BECACDE1","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/16a4c1e422b5dec818ee13eab3353b19db9cfd278cc10f9b0e1188a37671d9d4?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/16a4c1e422b5dec818ee13eab3353b19db9cfd278cc10f9b0e1188a37671d9d4?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/16a4c1e422b5dec818ee13eab3353b19db9cfd278cc10f9b0e1188a37671d9d4?s=96&d=mm&r=g","caption":"BECACDE1"},"sameAs":["http:\/\/www.cdealmeria.com"]}]}},"_links":{"self":[{"href":"https:\/\/www.cde.ual.es\/en\/wp-json\/wp\/v2\/posts\/67403","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.cde.ual.es\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.cde.ual.es\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.cde.ual.es\/en\/wp-json\/wp\/v2\/users\/101012"}],"replies":[{"embeddable":true,"href":"https:\/\/www.cde.ual.es\/en\/wp-json\/wp\/v2\/comments?post=67403"}],"version-history":[{"count":0,"href":"https:\/\/www.cde.ual.es\/en\/wp-json\/wp\/v2\/posts\/67403\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.cde.ual.es\/en\/wp-json\/wp\/v2\/media\/67414"}],"wp:attachment":[{"href":"https:\/\/www.cde.ual.es\/en\/wp-json\/wp\/v2\/media?parent=67403"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.cde.ual.es\/en\/wp-json\/wp\/v2\/categories?post=67403"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.cde.ual.es\/en\/wp-json\/wp\/v2\/tags?post=67403"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}